These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29683099)

  • 21. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG; Watts NB; Ebetino FH; Rogers MJ
    Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
    Fisher JE; Rodan GA; Reszka AA
    Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into the mevalonate pathway in the anticancer effect of a platinum complex on human gastric cancer cells.
    Qiu L; Yang H; Lv G; Li K; Liu G; Wang W; Wang S; Zhao X; Xie M; Lin J
    Eur J Pharmacol; 2017 Sep; 810():120-127. PubMed ID: 28666798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
    Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
    Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annatto tocotrienol improves indices of bone static histomorphometry in osteoporosis due to testosterone deficiency in rats.
    Chin KY; Abdul-Majeed S; Fozi NF; Ima-Nirwana S
    Nutrients; 2014 Nov; 6(11):4974-83. PubMed ID: 25389899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.
    Henneman L; van Cruchten AG; Kulik W; Waterham HR
    Biochim Biophys Acta; 2011 Apr; 1811(4):227-33. PubMed ID: 21237288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-cancer therapy: targeting the mevalonate pathway.
    Swanson KM; Hohl RJ
    Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
    Bauer DC
    Osteoporos Int; 2003 Jun; 14(4):273-82. PubMed ID: 12736772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis: From Molecular Mechanisms to Therapies.
    Tang CH
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of mevalonate pathway in osteogenic cells].
    Ishimi Y
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():779-82. PubMed ID: 15035226
    [No Abstract]   [Full Text] [Related]  

  • 31. [Anabolic effects of statin and beta-blocker on bone metabolism].
    Taguchi M; Takeuchi Y
    Clin Calcium; 2004 Dec; 14(12):89-94. PubMed ID: 15577180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tocotrienol from Bixa orellana (annatto) on bone histomorphometry in a male osteoporosis model induced by buserelin.
    Mohamad NV; Soelaiman IN; Chin KY
    Biomed Pharmacother; 2018 Jul; 103():453-462. PubMed ID: 29674281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strontium ranelate improves bone microarchitecture in osteoporosis.
    Hamdy NA
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv9-13. PubMed ID: 19783592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers.
    Mokarram P; Alizadeh J; Razban V; Barazeh M; Solomon C; Kavousipour S
    Curr Mol Pharmacol; 2017; 10(2):86-114. PubMed ID: 26758947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
    Yamada S; Inaba M; Nishizawa Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():348-51. PubMed ID: 18161129
    [No Abstract]   [Full Text] [Related]  

  • 36. Physiology of the aging bone and mechanisms of action of bisphosphonates.
    Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
    Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of statins for osteoporosis: a systematic review and meta-analysis.
    An T; Hao J; Sun S; Li R; Yang M; Cheng G; Zou M
    Osteoporos Int; 2017 Jan; 28(1):47-57. PubMed ID: 27888285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-osteoporotic drugs and vascular calcification: the bidirectional calcium traffic.
    Yavropoulou MP; Pikilidou M; Yovos JG
    J Vasc Res; 2014; 51(1):37-49. PubMed ID: 24280985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanisms of action of anticatabolic drugs used in osteoporosis therapy].
    Kryśkiewicz E; Lorenc RS
    Endokrynol Pol; 2009; 60(2):134-44. PubMed ID: 19396757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.
    Noa M; Mendoza S; Más R; Mendoza N; León F
    Drugs R D; 2004; 5(5):281-90. PubMed ID: 15357627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.